NCT00928486 - A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2009

Primary Completion Date

September 10, 2010

Study Completion Date

September 10, 2010

Conditions

Multiple Myeloma

Interventions

DRUG

Lenalidomide

Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle

DRUG

Dexamethasone

Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle

Trial Locations (8)

Nagoya Medical Center, Nagoya

Nagoya City University Hospital, Nagoya

Fukuoka University Hospital, Fukuoka

Kyoto Prefectural University of Medicine, Kyoto

Niigata Cancer Center Hospital, Niigata

Osaka Red Cross Hospital, Osaka

Tokushima University, Tokushima

Keio University Hospital, Tokyo